Analytical exoglycosidases are transitioning from being largely academic tools to being suitable for glycan analytics in biopharmaceutical manufacturing.
Xiaofeng Shi
Advertisement
Xiaofeng Shi is development group leader at New England Biolabs.
Articles by Xiaofeng Shi
Advertisement
Latest Updated Articles
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic DrugsPublished: October 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
4
Reducing CAR-T Manufacturing Times and Cost: Q&A with Trenchant’s Jon Ellis
5
